99mTc-MIBI imaging as a predictor of therapy response in osteosarcoma compared with multidrug resistance-associated protein and P-glycoprotein expression

Journal of Nuclear Medicine

Volumn 44, Issue 9, 2003, Pages 1394-1401

  Burak, Zeynep ^a   Moretti, Jean Luc ^b   Ersoy, Özden ^a   Sanli, Ulus ^a   Kantar, Mehmet ^a   Tamgac, Feyzi ^b   Basdemir, Gülçin ^a  

^a EGE UNIVERSITY SCHOOL OF MEDICINE   (Turkey)

^b AVICENNE HOSPITAL   (France)

Author keywords

99mTc methoxyisobutylisonitrile; Multidrug resistance; Multidrug resistance associated protein; Osteosarcoma; P glycoprotein

Indexed keywords

ANTINEOPLASTIC AGENT; GLYCOPROTEIN P; METHOXY ISOBUTYL ISONITRILE TECHNETIUM TC 99M; MULTIDRUG RESISTANCE PROTEIN; DIAGNOSTIC AGENT; RADIOPHARMACEUTICAL AGENT; TUMOR MARKER;

ADJUVANT CHEMOTHERAPY; ARTICLE; BIOPSY; CALCULATION; CANCER ADJUVANT THERAPY; CANCER DIAGNOSIS; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMAGING; IMMUNOHISTOCHEMISTRY; IN VIVO STUDY; INTERMETHOD COMPARISON; OSTEOSARCOMA; PREDICTION; PREOPERATIVE PERIOD; PRIORITY JOURNAL; PROTEIN EXPRESSION; SAMPLING; SCINTIGRAPHY; SCORING SYSTEM; TREATMENT OUTCOME; ADOLESCENT; ADULT; AGED; BONE TUMOR; CHILD; CLINICAL TRIAL; COMPARATIVE STUDY; DRUG EFFECT; FEMALE; FEMUR TUMOR; HUMERUS; MALE; METABOLIC CLEARANCE RATE; METABOLISM; MIDDLE AGED; PREDICTION AND FORECASTING; SCINTISCANNING; STATISTICS;

ADOLESCENT; ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BONE NEOPLASMS; CHILD; FEMALE; FEMORAL NEOPLASMS; HUMANS; HUMERUS; MALE; METABOLIC CLEARANCE RATE; MIDDLE AGED; MULTIDRUG RESISTANCE-ASSOCIATED PROTEINS; OSTEOSARCOMA; P-GLYCOPROTEIN; PREDICTIVE VALUE OF TESTS; RADIOPHARMACEUTICALS; STATISTICS; TECHNETIUM TC 99M SESTAMIBI; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL;

EID: 0142150278     PISSN: 01615505     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (32)

1. Gottesman MM, Pastan I. Biochemistry of multidrug resistance mediated by the multidrug transporter. Annu Rev Biochem. 1993;62:385-427.
2. Baldini N, Scotlandi K, Barbandi-Brodano G, et al. Expression of P-glycoprotein in high-grade osteosarcomas in relation to clinical outcome. N Engl J Med. 1995,333:1380-1385.
3. Broxterman HJ, Schuurhuis GJ. Transport proteins in drug resistance: detection and prognostic significance in acute myeloid leukemia. J Intern Med. 1997;242(suppl):147-151.
4. Ling V Multidrug resistance: molecular mechanisms and clinical relevance. Cancer Chemother Pharmacol. 1997;40(suppl):53-58
5. Zaman GJR, Flens MJ, van Leusden MR, et al. The human multidrug resistance-associated protein MRP is a plasma membrane drug-efflux pump. Proc Natl Acad Sci USA. 1994;91:8822-8826.
6. Serra M, Scotlandi K, Manara MC, et al. Analysis of P-glycoprotein expression in osteosarcoma. Eur J Cancer. 1995;31A:1998-2002.
7. Chan HSL, Grogan TM, Haddad G, Deboer G, Ling V P-glycoprotein expression critical determinant in response to osteosarcoma chemotherapy J Natl Cancer Inst. 1997,89:1706-1715.
8. Baldini G, Scotlandi K, Serra M, et al P-glycoprotein expression in osteosarcoma: a basis for risk-adapted adjuvant chemotherapy J Orthop Res. 1999,17:629-632.
9. Trieb K, Kotz R. Proteins expressed in osteosarcoma and serum levels as prognostic factors. Int J Biochem Cell Biol. 2001;33:11-17.
10. Nooter K, Burger H, Stoter G. Multidrug resistance-associated protein (MRP) in hematological malignancies. Leuk Lymphoma. 1996,20.381-387
11. Kao CH, Tsai SC, Wang JJ, Ho YJ, Ho ST, Changlai SP. Technetium-99m sestamethoxyisobutylisonitrile scan as a predictor of chemotherapy response in malignant lymphomas compared with P-glycoprotein expression, multidrug resistance-related protein expression and other prognosis factors. B J Haemathol 2001;113.369-374
12. Oda Y, Schneider-Stock R, Rys J, Gruchala A, Niezabitowski A, Roessner A Expression of multidrug resistance-associated protein gene in soft tissue sarcomas J Cancer Res Clin Oncol. 1996;122.161-165
13. Plaat BE, Hollema H, Molenaar WM, et al. Soft tissue leiomyosarcomas and malignant gastrointestinal stromal tumors: differences in clinical outcome and expression of multidrug resistance proteins. J Clin Oncol 2000;15.3211-3220.
14. 99mTc-MIBI imaging in patients with lung cancer. J Nucl Med 2001,42:1476-1483.
15. Oda Y, Dochorn-Dworniezak B, Jurgens H, Roessner A. Expression of multidrug resistance-associated protein gene in Ewing's sarcoma and malignant peripheral neuroectodermal tumor of bone. J Cancer Res Clin Oncol. 1997;123:237-239
16. Hendrikse NH, Frassen EJF, van der Graaf WTA, Vaalburg W, de Vries EGE. Visualization of multidrug resistance in vivo Eur J Nucl Med. 1999;26:283-293.
17. Piwnica-Worms D, Chiu ML, Budding M, Kronauge JF, Kramer RA, Croop JM Functional imaging of multidrug resistant P-glycoprotein with an organotechnetium complex Cancer Res. 1993;53 977-984.
18. 99mTc-MIBI in cells with P-glycoprotein mediated and multidrug resistance protein-associated multidrug resistance phenotypes Eur J Biochem 1998;15:140-146.
19. Del Vecchio S, Ciarmiello A, Potena MI, et al. In vivo detection of mutlidrug-resistant (MDR1) phenotype by technetium-99m sestamibi scan in untreated breast cancer patients Eur J Nucl Med. 1997;24:150-159.
20. Kostakoǧlu L, Kirath P, Ruacan Ş, et al Association of tumor washout rates and accumulation of technetium-99m MIBI with expression of P-glycoprotein in lung cancer. J Nucl Med. 1998;39:228-234.
21. 99mTc-MIBI scintigraphy in the assessment of MDR1 overexpreision in patients with musculoskeletal sarcomas-comparison with therapy response. Eur J Nucl Med 2001,28:1341-1350.
22. Cole S, Bhardwaj G, Gerlach JH, et al. Overexpression of a transporter gene in a multidrug-resistant human cancer cell line Science 1992;258:1650-1654
23. Aggarwal S, Gupta S A possible role for multidrug resistance-associated protein in the secretion of basic fibroblast growth factor by osteogenic sarcoma cell line (MG-63). Int J Ontol. 1998,13:1331-1334
24. Oda Y, Matsumoto Y, Harimaya K, Iwamoto Y, Tsuneyoshi M. Establishment of new multidrug-resistant human osteosarcoma cell lines. Oncol Rep 2000;7.859-866
25. Grant CE, Valdimarson G, Hipfner DR, Almquist KC, Cole SPC, Deeley RG. Overexpression of multidrug resistance associated protein (MRP) increases resistance to natural product drugs. Cancer Res. 1994;54:357-361.
26. Versantvoort CHM, Broxterman HJ, Bagry T, Sheper RJ, Twentyman PR Regulation by glutathione of drug transport in multidrug resistant human lung cell lines overexpressing multidrug resistance-associated protein Br J Cancer 1995;72:82-89.
27. Moretti JL, Duran-Cordobes M, Starzec A, et al Involvement of glutathione in loss of technetium-99m-MIBI accumulation related to membrane MDR protein expression in tumor cells. J Nucl Mud. 1998;39:1214-1218.
28. Lewis AD, Hichson ID, Robson CN, et al. Amplification and increased expression of alpha class glutathione S-transferase encoding genes associated with resistance to nitrogen mustard. Proc Natl Acad Sci USA. 1988;85.8511-8517
29. Komiya S, Gebhardt MC, Mangham DC, Inoue A. Role of glutathione incisplatin resistance in osteosarcoma cell lines J Orthop Res 1998;16:15-22.
30. Uozaki H, Horiuchi H, Ishida T, Iijima T, Imamura T, Machinami R. Overexpression of resistance-related proteins (metallothioneins, glutathione-S-transferase pi, heat shock protein 27 and lung resistance-related protein) in osteosarcoma: relationship with poor prognosis. Cancer. 1997;15:2336-2344.
31. Bodey B, Taylor CR, Siegel SE, Kaiser HE. Immunohistochemical observation of multidrug resistance (MDR) p170 glycoprotein expression in human osteosarcoma cells: the clinical significance of MDR overexpression Anticancer Res. 1995;15:2461-2468.
32. Wunder JS, Bull SB, Aneliunas V, et al. MDR1 gene expression and outcome in osteosarcoma: a prospective, multicenter study. J Clin Oncol. 2000,18:2685-2694.